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In this study, we present enzymatic differences found between recombinant RTs derived from feline leukemia virus and feline
immunodeficiency virus. Firstly, FIV RT showed low steady state Km values for dNTPs compared to FeLV RT. Consistent with this, FIV RT
synthesized DNA more efficiently than FeLV RT at low dNTP concentrations. We observed similar concentration-dependent activity
differences between other lentiviral (HIV-1 and SIV) and non-lentiviral (MuLV and AMV) RTs. Second, FeLV RT showed less efficient
misincorporation with biased dNTP pools and mismatch primer extension capabilities, compared to FIV RT. In M13mp2 lacZa forward
mutation assays, FeLV RT displayed approximately 11-fold higher fidelity than FIV RT. Finally, FeLV RT was less sensitive to 3TCTP and
ddATP than FIV RT. This study represents the comprehensive enzymatic characterization of RTs from a lentivirus and a non-lentivirus
retrovirus from the same host species. The data presented here support enzymatic divergences seen among retroviral RTs.
D 2005 Elsevier Inc. All rights reserved.Keywords: FIV; FeLV; Reverse transcriptaseIntroduction
Retro-elements, including retroviruses, are characterized
by their unique process of replicating single-stranded
positive sense genomic RNA into double-stranded DNA,
and have been widely identified in various host species from
yeast (e.g., Ty elements) to humans (e.g., retroviruses).
Animal retroviruses have been extensively studied due to
their pathological roles in various diseases of infected hosts.
Family Retroviridae is phylogenetically classified into seven
distinct groups based upon their genomic sequences (Fields
et al., 2001). However, with the exception of non-
pathogenic spumaviruses, animal retroviruses have been
pathologically classified into two major groups: the immu-
nodeficiency causing lentiviruses (e.g., human, simian, and
feline immunodeficiency viruses [HIV-1, SIV, and FIV,
respectively]), and the cancer causing oncoretroviruses (e.g.,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to this work.human and simian T cell leukemia viruses [HTLV and
STLV, respectively], murine leukemia virus [MuLV], and
feline leukemia virus [FeLV]).
These two groups of retroviruses also exhibit differences
in cell type-specific infection. Lentiviruses efficiently infect
both non-dividing/terminally-differentiated cells (i.e., mac-
rophage) and dividing cells (i.e., activated T cells), whereas
most oncoretroviruses studied thus far only productively
replicate in dividing cells during natural infections (Gendel-
man et al., 1986; Lewis and Emerman, 1994; Lewis et al.,
1992; McGuire and Henson, 1971). The exception to this
generalization would be Avian Sarcoma Virus (ASV), which
has been shown to infect non-dividing cells (Greger et al.,
2004). However, actively dividing avian cells such as
chicken embryo fibroblasts have been used for the
productive viral replication and culture of this virus (Estis
and Temin, 1979).
All retroviruses encode their own DNA polymerase,
called reverse transcriptase (RT). RT catalyzes both RNA-
and DNA-dependent DNA polymerization reactions that
synthesize the () and (+) strands of the proviral DNA,05) 106 – 121
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during replication. The RTs from HIV-1 (a lentivirus) and
MuLV (an oncoretrovirus) are the most extensively charac-
terized RTs, in terms of enzymology and structure (Skalka
and Goff, 1993). These two RTs share general enzyme
activities essential for viral replication, such as DNA
polymerase and RNase H activities (and the resulting strand
transfer action). They also share similar structural organ-
izations (Georgiadis et al., 1995; Jacobo-Molina et al., 1993;
Kohlstaedt et al., 1992). Their DNA polymerase domains,
consisting of the fingers, palm and thumb sub-domains, lie
at their N-terminal regions, while the RNase H sub-domain
is located at their C-terminal regions. MuLV RT (¨71 kDa)
is slightly larger than HIV-1 RT (¨66 kDa) mainly due to its
larger fingers sub-domain. In addition, MuLV RT (and
Bovine Leukemia Virus [BLV] RT) functions as a monomer
(Avidan et al., 2002; Perach and Hizi, 1999), whereas HIV-1
RT acts as a p66/p51 heterodimer (Kohlstaedt et al., 1992).
Several enzymatic differences between HIV-1 and MuLV
RTs have also been observed. Firstly, HIV-1 RT appears to
have lower steady state Km values for dNTP substrates
compared to MuLV RT, although these kinetic differences
vary significantly depending on the properties and sequences
of the template-primers used in the study (Chowdhury et al.,
1996; Diamond et al., 2003; Furge andGuengerich, 1997; Shi
et al., 2002). This indicates that HIV-1 RT can synthesize
DNA more efficiently than MuLV RT at low dNTP
concentrations. In keeping with this, our recently published
data indicate that HIV-1 RT has a higher binding affinity for
dNTPs compared to MuLV RT (Skasko et al., 2005). Further
data generated by our lab have shown that the dNTP
concentration in terminally differentiated/non-dividing
human macrophage (¨40 nM) is 50–100 times lower than
activated human CD4+ T cells (2–5 AM) (Diamond et al.,
2004) . Because the ability of an RT to efficiently incorporate
dNTPs in different dNTP concentration environments may
place limitations on the different types of cells that a
particular retrovirus may infect, our combined data suggest
that the ability of HIV-1 RT to efficiently synthesize DNA at
low dNTP concentrations may contribute to the unique
capability of HIV-1 to infect nondividing cells such as
macrophages.
Secondly, HIV-1 and MuLV RTs differ in their fidelity of
DNA polymerization. HIV-1 RT has an error rate of 2.5–5
104 mutations per nucleotide copied, a rate 15 times higher
than that of MuLV RT (Bebenek et al., 1989; Preston et al.,
1988; Roberts et al., 1989; Williams and Loeb, 1992). Other
lentiviral RTs, such as SIV RT (Diamond et al., 2001) and
Equine Infectious Anemia Virus RT (Bakhanashvili and Hizi,
1993), are also unfaithful DNA polymerases with error rates
similar to that of HIV-1 RT. In addition, RT proteins of
oncoretroviruses, such as those from mouse mammary tumor
virus (MMTV, Taube et al., 1998a, 1998b), Moloney murine
leukemia virus (MoMuLV, Roberts et al., 1989), avian
myeloblastosis virus (AMV, Battula and Loeb, 1974; Roberts
et al., 1989), and BLV (Avidan et al., 2002; Perach and Hizi,1999), all of which have been successfully purified, show
higher fidelity than lentiviral RTs. The fidelity difference
between lentiviral and oncoretroviral RTs implies that the
active sites of RTs from these two major groups of
retroviruses may have different molecular architectures. It
has also been reported that the lower capability of MuLV RT
to extend mismatched primers contributes to its high
replication fidelity (Bakhanashvili and Hizi, 1992). There
are several lines of evidence that support that the fidelity of
retroviral RTs contributes to viral genomic mutagenesis. A
study by O’Neil et al. (2002) which analyzed mutations in
HIV-1 LTRs during a single round of replication using both
HIV-1 RT and RNA pol II, suggested that HIV-1 RT, and not
host RNA pol II, plays a primary role in the genomic
mutagenesis of HIV-1. Recent reports demonstrated that
alterations in enzymatic fidelity of HIV-1 RT affect viral
genomic mutagenesis during a single round of viral
replication (Mansky et al., 2003; Weiss et al., 2004). These
biochemical and virological findings suggest that replication
fidelity of retroviral RTs contributes to viral mutagenesis.
Thirdly, MuLV RTshows less sensitivity to nucleotide RT
inhibitors (NRTIs), particularly to NRTIs containing modi-
fied L-form sugar moieties such as 3TCTP (Back et al., 1996;
Cherrington et al., 1996). Structural studies suggest that the
amino acid sequence variation of residue FX_ within the
conserved YXDD catalytic sites of HIV-1 RT (YMDD) and
MuLV RT (YVDD) contribute to their different sensitivities
to 3TCTP (Rezende et al., 1998). Accordingly, clinical
observations show that HIV-1 isolates containing M184I
and M184V RT mutations display 3TC resistance (Back et
al., 1996; Wainberg et al., 1996). Additionally, a Met-to-Thr
mutation at the FX_ residue found in mutants of FIV RT was
shown to also confer resistance to 3TC (Smith et al., 1997).
The FX_ residue in the YXDD motif is also important in the
enzyme fidelity of retroviral RTs. Mutants of MuLV RT
containing Met or Ala at the YXDD motif, instead of the
wild-type Val, exhibit decreased replication fidelity (Kaushik
et al., 2000b), while the Val and Ile mutations in the YXDD
motif of HIV-1 RT enhance fidelity (Rezende et al., 1998).
Several oncoretroviruses and lentiviruses have been
identified from a single host species (e.g., HTLV-1 and
HIV-1). However, it has been difficult to perform parallel
biochemical characterizations of lentiviral and oncoretro-
viral RTs isolated from a single host species, mainly due to
difficulties in purifying large amounts of active RT
proteins from the oncoretroviruses in these hosts. A
parallel study of this sort would be useful in determining
if the enzymatic differences found between lentiviral and
oncoretroviral RTs studied thus far are preserved when two
retroviruses from different retroviral groups evolve in the
same host species. Moreover, the cell type specificity of
these retroviruses as related to their respective RTs is
biochemically relevant. Most oncoretroviral RTs success-
fully purified thus far (e.g., RTs of MuLV, AMV, and
MMTV) have been isolated from oncoretroviruses in host
species where a lentivirus has yet to be identified. While
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(Owen et al., 1998; Trentin et al., 1998), it has not been
purified in sufficient amounts to be able to compare to its
HIV-1 counterpart. BLV RT has also been previously
isolated (Avidan et al., 2002; Perach and Hizi, 1999), but
has not been compared with BIV RT. In this study, we
have successfully purified active RTs from both FeLV (an
oncoretrovirus, genus gammaretrovirus) and FIV (a
lentivirus), retroviruses that infect the same host species.
Results from enzymatic comparison between FeLV and
FIV RTs support conserved enzymatic divergences
between RTs of lentiviruses and oncoretroviruses. Possible
virological contribution of the enzymatic differences
between lentiviral and oncoretroviral RTs are discussed.Results
Cloning and purification of FeLV and FIV RTs
The RTs used in the work presented below are derived
from FIV (strain PPR) and FeLV (strain 61E). FIV-PPR
infects feline macrophage and peripheral blood leukocytes
(Phillips et al., 1990). Infection with FIV causes immuno-
deficiency disease with a clinical course similar to that
found with HIV disease in humans, and as such has been
proposed as a small animal model for HIV/AIDS disease in
humans (Bendinelli et al., 1995; Torten et al., 1991). In
contrast, FeLV-61E induces lymphosarcoma, and is feline T
cell-tropic (Overbaugh et al., 1988). Both recombinant
untagged FIV RT (North et al., 1994) and GST-tagged
FIV RT (Amacker et al., 1995) proteins have previously
been purified. While FeLV RT has been previously isolated
from virions (Rho and Gallo, 1980), no recombinant FeLV
RT has been purified thus far.
FeLV and FIV RT genes (2001 bp and 1677 bp,
respectively) were amplified from molecular clones, pFIV-
PPR (Phillips et al., 1990; Talbott et al., 1989) and p61E
(Donahue et al., 1988; Overbaugh et al., 1988), respec-
tively (NIH AIDS Research and Reference Reagent
Program). The 5V and 3V ends of the coding regions for
both RTs were determined by aligning them against the
Asp residues of the conserved YXDD motif of HIV-1 and
MuLV RTs (i.e., Asp185 of HIV-1 RT and Asp224 of
MuLV RT). The amino acid sequences of FeLV and FIV
RTs near the active site, as well as those sequences at the
N- and C-terminal ends of the proteins were compared
with those of other oncoretroviral (MuLV and Friend
MLV) and lentiviral (HIV-1, HIV-2 and SIVmac239) RTs,
respectively (Fig. 1A). As shown in Fig. 1A, the three
catalytically essential Asp residues (each indicated as a
bold FD_) known to interact with metal ions in HIV-1 RT
(Huang et al., 1998; Kohlstaedt et al., 1992) and the
adjacent residues are highly conserved between FeLV RT
and the three other oncoretroviral RTs, as well as between
FIV RT and the three other lentiviral RTs (Fig. 1A). FeLVRT, like MuLV and Friend MLV RTs, has a Val residue at
X in the YXDD motif, whereas the analogous sequence
found in FIV RT is similar to that of the other three
lentiviral RTs. In addition, the residues known to be
important in enzymatic fidelity of HIV-1 and MuLV RTs
are also observed in FIV and FeLV RTs (see references in
Fig. 1A legend).
FeLV and FIV RT expression plasmids were constructed
by cloning the amplified RT genes into pET28a (Novagen,
WI), giving the expressed proteins cleavable 6-His tags.
The proteins were purified from bacterial overexpression
systems using Ni2+ affinity columns (see details in
Materials and methods). The RT proteins initially eluted
from the Ni2+ columns had considerable contamination as
shown in Fig. 1B (Ni). The eluted proteins were therefore
treated with Thrombin to cleave the N-terminal 6-His tag,
and then applied to a fresh Ni2+ column. This second
column was used to remove cleaved hexahistidine tags as
well as contaminants that non-specifically bound to the first
column. The flow-through fractions containing cleaved RT
proteins (unbound) were collected for analysis. As shown in
Fig. 1B (Thr), Thrombin treatment increased the purity of
both FeLV and FIV RT proteins. The observed sizes of
FeLVand FIV RT proteins were similar with those of MuLV
and p66 HIV-1 RT proteins, respectively (see Fig. 1B).
Using this purification system, we were able to purify
approximately 0.2 mg of FeLV RT and 0.5 mg of FIV RT,
each from 1 L culture. Both enzymes were tested for
polymerase activity using poly (rA)/oligo (dT) (data not
shown) as well as heteropolymeric RNA and DNA
templates (see below), and both purified RTs were found
to be highly active. Purified RT proteins were also tested for
bacterial RNase contamination by incubating the RTs with a
32P-labeled RNA template annealed to DNA primer in the
absence of dNTP, and no significant degradation of RNA
template was observed, compared to ‘‘No RT control’’ (data
not shown). The successful purification of these recombi-
nant proteins allows us to perform the first comparative
characterization of RT proteins derived from a lentivirus and
oncoretrovirus isolated from the same host species.
Steady state kinetic analysis of FIV and FeLV RTs
In order to compare enzymatic properties of the purified
FeLV and FIV RT proteins, we performed steady state
single nucleotide incorporation assays using an RNA
template. For this assay, four different 5V 32P-labeled
primers, which were individually annealed to a 38-mer
RNA template, were extended by RTs in the presence of
each of the four individual dNTPs. Km and kcat values were
determined for both RTs. As shown in Fig. 2A, the kcat
values of both FIV and FeLV RT proteins were similar.
However, the Km values of FeLV RT for dNTPs were
16–58 times higher than that of FIV RT. Fig. 2B shows
that FeLV RT maintains its maximum dCTP incorporation
rate above 5 AM (lane 4, FeLV RT), while FIV RT is able
Fig. 1. Amino acid sequence comparison and purification of FeLV and FIV RTs. (A) Amino acid sequence comparison of four RTs of lentiviruses (FIV-PPR,
HIV-1 HXB2, HIV-2 ST, and SIVmac239) and three RTs of oncoretroviruses (FeLV-61E, MuLV, and Friend MLV) at their fingers domain interacting with
template and the palm domain containing three Asp residues that are catalytically important (bold) as well as both N- and C-terminal ends of the proteins. The
conserved YXDD domains are underlined. Residue numbers of HIV-1 and MuLV RTs are marked at the first of last residues of each region. Residues known to
be important for the fidelity of HIV-1 RT and MuLV RT are marked by ‘‘*’’: D76 (Kim et al., 1996, 1999), R78 (Kim et al., 1999), Y115 (Cases-Gonzalez et al.,
2000) V148 (Diamond et al., 2003), and Q151 (Kaushik et al., 1997; Weiss et al., 2002) of HIV-1 RT, F155 (equivalent to F119 in MMTV RT) (Entin-Meer et
al., 2002), Q190 (Singh et al., 2000), and V223 (Kaushik et al., 2000a) of MuLV RT. These RT sequences were obtained from Gene Bank: FIV-PPR (GenBank
accession no. M36968), HIV-1 HXB2 (GenBank accession no. NC_001802), HIV-2 ST (GenBank accession no. M31113), SIVmac239 (GenBank accession
no. M33262), FeLV p61E (GenBank accession no. M18247), MuLV (GenBank accession no. NC_001501) and Friend MLV (GenBank accession no. NC_
001362). Lentiviral RT overall sequence homology was 22.6% over all four proteins, and 47.3% between HIV-1 and FIV RTs specifically. Oncoretroviral RT
overall sequence homology was 74.6% between the three proteins, and 75.3% between MuLV and FeLV RTs specifically. (B) SDS-PAGE (12%) for purified
RT proteins. Ni: His-tagged FeLV and FIV RT proteins eluted from Ni2+ column, Thr: RT proteins collected from a second Ni2+ column after the Thrombin
treatment. Purified MuLV (M) and HIV-1 RT (H) proteins were used for the size comparison. Molecular weight markers (MW, kDa) are also shown.
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trations as low as 0.25 AM (lane 7, FIV RT), reflecting the
higher Km values of FeLV RT compared to FIV RT.
Interestingly, HIV-1 RT has been shown to have lower Km
values for dNTPs than MuLV RT, even though this Km
difference depends on the template/primer (T/P) and type of
assay (single vs. multiple nucleotide incorporation)
employed in the studies (Chowdhury et al., 1996; Diamond
et al., 2001, 2004; Furge and Guengerich, 1997; Shi et al.,
2002; Ueno et al., 1995; Woodside and Guengerich, 2002).
Yet another lentiviral RT, SIV RT (SIVMNE CL8 RT), also
has low Km values (¨50 nM, Diamond et al., 2001). These
data suggest that FIV RT, like HIV and SIV RTs, canincorporate dNTPs much more efficiently than FeLV RT at
low dNTP concentrations.
dNTP concentration dependent DNA polymerase activity of
lentiviral and oncoretroviral RT proteins
The steady state kinetic studies shown in Fig. 2 suggested
that FIV RT utilizes dNTPs more efficiently than FeLV RTat
low dNTP concentrations. We tested whether differences in
DNA synthesis efficiency at low dNTP concentrations
between FIV and FeLV RTs were also true between other
lentiviral and oncoretroviral RTs. For this, we employed
HIV-1 and MuLV RTs for comparison.
Fig. 2. Steady state kinetic analysis of FeLV and FIV RT proteins. (A) Steady state kinetic parameters of FeLV and FIV RTs in incorporation of dNTPs. Fold
differences of Km values between FIV and FeLV RTs were shown in parentheses. These kinetic values were obtained from three independent experiments.
Standard deviations were <25%. (B) dCTP incorporation by FeLVand FIV RTs. 32P-labeled 17-mer Extend-C primer annealed to a 38-mer RNA template was
extended by 10 mM RT proteins for 5 min with decreasing concentrations of dCTP (50, 25, 12.5, 5, 1, 0.5, 0.25, 0.125, 0.06, and 0.03 AM for FeLV RT or 12.5,
5, 1, 0.5, 0.25, 0.125, 0.06, 0.03, 0.015, and 0.008 AM for FIV RT). Reactions were analyzed on a 14% denaturing polyacrylamide-urea gel. E: extended
primer, S: unextended primer.
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17-mer A-primer (See Materials and Methods) annealed to a
38-mer RNA template. Primer extension by the RT proteins
was assayed in the presence of all four dNTPs at four different
concentrations. For this, we first determined the amount ofFig. 3. dNTP concentration dependence of primer extension two lentiviral and two
38-mer RNA template was extended by an equivalent activity of two lentiviral RTs
RTs, showing approximately 50% primer extension with 25 AM dNTPs (10 nM HI
lane in each RT reaction) at 37 -C for 5 min. The reactions were repeated with thre
AM). Reaction conditions and RT concentrations used were described in Materials
gel. F: fully extended products, S: unextended primer.protein that yielded full extension of approximately 50% of
primer (see ‘‘F’’ in Fig. 3) with 250 AM dNTPs (for each
dNTP) at 37 -C for 5 min. Note that 250 AM dNTP is much
higher than the Km values of both oncoretroviral RTs and
lentiviral RTs used in this study (Fig. 2A). Next, the primeroncoretroviral RT proteins. The 32P-labeled 17-mer A-primer bound to the
(A), FIV and HIV-1 RTs, and two oncoretroviral RTs (B), FeLVand MuLV
V-1 RT, 40 nM FIV RT, 5 nM MuLV RT, and 60 nM FeLV RT, see the first
e different decreasing concentrations of dNTPs (2.5 AM, 0.25 AM, and 0.05
and methods. Reactions were analyzed on a 14% denaturing polyacrylamide
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concentrations, 2, 0.2, and 0.05 AM, with the same amount of
RNA-dependent DNA polymerization (RDDP) activity of
RT proteins used with the 25 AM dNTP reactions. As
observed in Fig. 3, the oncoretroviral RTs showed dramatic
decreases in polymerization activity in reactions containing
low dNTP concentrations, whereas the lentiviral RTs main-
tained significant RDDP activity (Fig. 3A) even at the low
dNTP concentrations (0.2 and 0.05 AM). Our recent studies
also demonstrated that SIVMNE CL8 RT, but not AMV RT,
showed efficient DNA synthesis at low dNTP concentrations
(Diamond et al., 2004) which is consistent with the low Km
value of SIVMNECL8RT for dNTPs (Diamond et al., 2003).
Therefore, the data presented here with FIVand FeLVRTs are
consistent with the idea that lentiviral RTs efficiently
synthesize DNA at low dNTP concentrations compared to
oncoretroviral RTs.
Misincorporation assay of FIV and FeLV RTs
Next, we examined the fidelity of FIV and FeLV RT
proteins using the misincorporation assay. The low-fidelity
HIV-1 RT and high-fidelity MuLV RT were also included
for comparison. The misincorporation assay is a primer
extension assay which qualitatively monitors both mis-
insertion and mismatch extension in the presence of biased
dNTP pools containing only three of the four natural
dNTPs. Assays were performed using 32P-labeled 17-mer
A-primer annealed to the 38-mer RNA or DNA template.
In the absence of one of the dNTPs, primer extension stalls
one base before the template nucleotide for which theFig. 4. Misincorporation assay. The 32P-labeled 17-mer primer (‘‘S’’: A-primer) an
(A), FIV and HIV-1 RTs, and two oncoretroviral RTs (B), FeLVand MuLV RTs, at
all 4, or only 3 complementary dNTPs (minus dGTP or minus dCTP). The two s
approximately 20 (1) and 80 (4) % of the primer extension with all 4 dNTPs w
urea denaturing gel. The sequence of the extended part of the primer is shown. F: f
sites. The sequence of the first 4 nucleotides in the extended part of the primer icomplementary dNTP is withheld (‘‘stop site’’; indicated
by asterisks ‘‘*’’ in Fig. 4). A higher efficiency of primer
extension beyond the stop site reflects higher ability to
utilize incorrect dNTPs, or lower fidelity of the RT. Under
our reaction conditions, the small amount of potential
contamination by correct dNTP does not significantly
contribute to the observed results, as previously shown
(Diamond et al., 2003). Initially, we determined RT
concentrations that gave approximately 20% (1) and
80% (4) of primer extension, as estimated from the
amount of fully extended primer (‘‘F’’ in Fig. 4) following
a 5-min incubation at 37 -C in the presence of all four
dNTPs (250 AM). This dNTP concentration is well above
the Km values for all RT proteins tested, therefore allowing
reactions to proceed at dNTP saturation. When incubated
with mixtures of only three dNTPs (Fig. 4: minus dGTP or
minus dCTP), FIV and HIV-1 RTs catalyzed substantial
extension past the stop sites on RNA templates (*),
indicating their low fidelity. However, under the same
reaction conditions, FeLV RT behaved similar to MuLV
RT, catalyzing less efficient extension beyond the stop sites
than the two lentiviral RT proteins (Fig. 4), indicating
higher replication fidelity. In addition, FeLV and MuLV
RTs are similar in their misincorporation fidelities, as
judged by the amount of the primer extension beyond the
first stop site. Similar differences were observed in minus
dATP and minus dTTP reactions as well as in reactions
with DNA templates (data not shown). We previously
showed that SIV RT (CL8, Diamond et al., 2001, but not
AMV RT Kim et al., 1999), showed efficient primer
extension beyond the stop sites in similar assays.nealed to 38-mer RNA template was extended by RTs of two lentiviral RTs
37 -C for 5 min. The extension reactions were performed in the presence of
ame RT activities (see Materials and methods) of each RT protein showing
ere used in this assay. The reactions were analyzed by 14% polyacrylamide-
ully extended 38-nucleotide-long products, S: unextended primer, ‘‘*’’: stop
s shown.
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Creation of a mutation during DNA synthesis involves
two sequential steps: (1) incorporation of an incorrect
dNTP, or misinsertion, and (2) extension past the
mismatch generated by the misinsertion. In the misincor-
poration assay shown in Fig. 4, extension of the primer
beyond the stop site measures the capability of the RT
proteins to both misinsert and to extend the mismatched
primer. Next, we examined the capability of FIV and
FeLV RT proteins to perform only the second step of
mutation synthesis, the extension of a mismatched primer
terminus. In this assay, we used two different mismatched
primers annealed to either RNA or DNA template. One
T/P contains a G/T mismatch at the 3V end of the primer
annealed to an RNA template. The other T/P contains a
C/A mismatch at the 3V end of the primer annealed to a
DNA template. These G/T (1st DNA strand synthesis) and
C/A (2nd DNA strand synthesis) mismatched T/Ps
represent replication intermediates encountered during the
process of G to A mutation, the predominant lentiviral
mutation (Vartanian et al., 1991). While the G to A
transitions that arise during HIV-1 replication can occur by
the actions of APOBEC3G (Gu and Sundquist, 2003;
Sheehy et al., 2002; Vartanian et al., 2003), the
contribution of misinsertion/misincorporation by HIV-1
RT to this type of mutation cannot be ruled out. We tested
whether FeLV RT (and MuLV RT) has a reduced
capability to extend these two mismatched T/Ps, compared
with FIV RT (and HIV-1 RT). The G/T and C/AFig. 5. Extension of two mismatched primers by FIVand FeLV RT proteins. The 32
annealed to 38-mer RNA and DNA templates, respectively, were extended by the sa
min. The extension reactions were performed in the presence of all 4 dNTPs. Rea
methods. The reactions were analyzed by 14% polyacrylamide-urea denaturin
mismatched primer.mismatched primers (‘‘MP’’ in Fig. 5) were extended with
the same amount of DNA polymerase activities (4 and
1) of FIV, FeLV, HIV-1, and MuLV RTs as used in the
misincorporation assay (see ‘‘All dNTPs’’ in Fig. 4) for 10
min. Extension of these mismatched primers in the
presence of all four dNTPs generated the 38 nucleotide
long product (FF_ in Fig. 5). As shown in Figs. 5A and B,
the two oncoretroviral RTs showed less efficient extension
from both G/T (Fig. 5A) and C/A (Fig. 5B) mismatched
primers than FIV and HIV-1 RTs. These data suggest that,
like MuLV RT, FeLV RT has higher mismatch extension
fidelity than FIV RT and HIV-1 RT.
M13mp2 lacZa forward mutation assay
To verify the fidelity differences observed between
FeLV and FIV RTs in the gel based assays, we measured
fidelity of FeLV and FIV RTs using the M13mp2 lacZa
forward mutation assay (Bebenek and Kunkel, 1995).
Three independent gap-filling reactions of FIV and FeLV
RTs using the M13 lacZa gapped DNA substrate were
performed, each over a 20-min reaction time. The mutant
frequency of each RT was determined as the ratio of
mutant (pale blue or clear) plaques to total plaques
counted. As shown in Table 1, FeLV RT displayed
approximately 11-fold lower mutant frequency than FIV
RT. In fact, the mutation rate of FIV RT is comparable to
that previously observed with HIV-1 RT (Preston et al.,
1988). Previous studies have shown that MuLV RT has 15-
fold higher fidelity than HIV-1 RT in the same M13mp2P labeled mismatched G/T 16-mer (A) and C/A 19-mer (B) primers (‘‘MP’’)
me two quantities (4 and 1) of RT proteins used in Fig. 4 at 37 -C for 10
ction conditions and RT concentrations used are described in Materials and
g gel. F: fully extended 38-nucleotide-long products, MP: unextended
Table 1
Mutant frequency of FeLV and FIV RT proteins determined by M13mp2











FIV RT 14,220 134 0.00942 X11
FeLV RT 15,820 14 0.00088 X1
a Numbers of plaques obtained from three independent gap-filling
reactions.
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Therefore, together with the results from the misincorpora-
tion assay (Fig. 4) and mismatch extension assay (Fig. 5),
these data demonstrate that FeLV RT has higher fidelity
than FIV RT.
Mg2+ vs. Mn2+ usage by RT proteins
Previous reports have also indicated that HIV-1 RT
performs optimally in the presence of Mg2+ while Moloney
Murine Sarcoma-Leukemia Virus RT has optimal perform-
ance with Mn2+ (Gerard and Grandgenett, 1975; Valverde-
Garduno et al., 1998). Using poly(rA)/oligo(dT) as a
substrate, we tested the activity of FIV and FeLV RTs in
the presence of two different concentrations (5 and 0.05
mM) of these divalent cations, using HIV and MuLV RTs
for comparison. HIV-1 RT and FIV RT show higher activity
with 5 mM Mg2+, but can effectively use Mn2+ at 0.05 mM.
In contrast, MuLV and FeLV RTs show significantly higher
activities in the presence of 0.05 mM Mn2+, but does not
efficiently use Mg2+ in comparison (Fig. 6).Fig. 6. Mg2+ and Mn2+ dependence of RT Activity. RT proteins were tested
homopolymeric template/primer complex as a substrate in the presence of either 5
presented such that the total cpm values incorporated in the presence of the preferre
activities in the presence of the metal conditions. Each experiment was performeSensitivity of FeLV and FIV RTs to 3TCTP, AZTTP, and
ddATP
It has been demonstrated that RTs that contain the Val
residue in the conserved YXDD sequence (e.g., MuLV RT)
display inefficient incorporation of 3TCTP, compared to
RTs that contain the Met residue (e.g., HIV-1 RT) (Gao et
al., 2000; Rezende et al., 1998). This inefficient 3TCTP
incorporation is also observed in 3TC-resistant HIV-1 RT
variants that contain the Val residue in the YXDD sequence
(Gao et al., 2000; Miller et al., 2002; Sarafianos et al.,
1999). Since RTs of FeLV and FIV contain Val and Met
residues, respectively, we compared the sensitivity of FeLV
and FIV RTs to 3TCTP, using the primer extension reaction
that is similar with the assay previously used (Klarmann et
al., 2000). We also compared the AZTTP and ddATP
sensitivity of FeLV and FIV RTs. For this, the 17-mer A-
primer annealed to the 38-mer RNA template was extended
by RT proteins showing approximately 80% of primer
extension with 10 AM dNTPs (see 4 in Fig. 4). The
reactions were then repeated in the presence of mixtures of
10 AM dNTPs and various concentrations of 3TCTP,
AZTTP and ddATP. As shown in Fig. 7A, FeLV RT
showed low sensitivity to 3TCTP, compared to FIV RT. We
see that FIV RT was inhibited by 3TCTP even at the lower
concentrations of 3TCTP tested. We calculated an IC50 for
3TCTP of approximately 150 AM for FIV RT, consistent
with a previous report by Smith et al. (1997). Because FeLV
RT showed a very low sensitivity to 3TCTP, we were unable
to determine an IC50 even with the highest 3TCTP
concentration (400 AM, Fig. 7A). However, the IC50 offor their preference of metal in RT polymerization activity by using a
mM or 0.05 mM divalent cation (see Materials and methods). The data are
d metal ion (and preferred concentration) is set to 1, with the relative percent
d in duplicate.
Fig. 7. 3TCTP, AZTTP and ddATP sensitivity of FeLV and FIV RTs. The
32P-labeled 17-mer A-primer annealed to the 38-mer RNA template was
extended by FIV (closed square) and FeLV (open circle) RT proteins
showing approximately 75% of the primer extension (see Materials and
methods) with dNTPs (10 AM each, no drug) at 37 -C for 5 min. The
extension reactions were repeated in the presence of four dNTPs (10 AM
each) and increasing concentrations of 3TCTP (A), AZTTP (B) and ddATP
(C). The reactions were analyzed by 14% polyacrylamide-urea denaturing
gel. Percent of fully extended products at different concentrations of
inhibitors were plotted to determine the drug concentrations showing 50%
inhibition (IC50).
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than that of FIV RT. Unlike 3TCTP, these two enzymes
showed similar sensitivity to AZTTP, showing IC50s of 42AM and 60 AM for FIV RT and FeLV RT, respectively (Fig.
7B). ddATP also effectively inhibited FIV RT. An 80%
inhibition was observed even at the lowest concentration
tested. We calculated an IC50 of approximately 15 AM for
ddATP against FIV RT. While not being inhibited as
dramatically as FIV RT, FeLV RT was able to be inhibited
by ddATP at the high AM range, with an IC50 of
approximately 280 AM (Fig. 7C).Discussion
This study describes the characterization of active
recombinant RT proteins from an oncoretrovirus (FeLV)
and lentivirus (FIV) isolated from a single host species. RT
proteins from FeLV and FIV were produced from bacterial
overexpression systems and further purified by reverse Ni2+
column chromatography after the removal of the hexahisti-
dine tag from both RT proteins. Both purified RT proteins
were highly active as shown by their steady state kcat values
(Fig. 2A), and by primer extension reactions (see Fig. 4, ‘‘All
dNTPs’’).We investigated the enzymatic differences between
FeLVand FIV RT proteins and compared themwith retroviral
RTs previously characterized (e.g., RTs of HIV-1, SIV,MuLV
and AMV). This study therefore presents the first extensive
biochemical comparison of oncoretroviral and lentiviral RTs
isolated from a single host species.
RTs of FeLV and FIV displayed clear differences in their
steady state kinetics. As shown in Fig. 2A, FeLVand FIV RTs
showed similar kcat values, indicating that the enzyme
preparations were equally active. These values are also
similar with those of MuLV and HIV-1 RTs previously
reported (Preston et al., 1988; Roberts et al., 1989). However,
FeLV RT showed higher Km values than FIV RT for each of
the four dNTPs (Fig. 2A). Differences in Km values for the
incoming dNTPs have also been observed between MuLV
and HIV-1 RTs as well as in SIV RT in previous kinetic
studies (Chowdhury et al., 1996; Diamond et al., 2001; Furge
and Guengerich, 1997). Importantly, the lower Km values of
FIV RT (and HIV-1 RT) indicate that FIV RT efficiently
incorporates dNTP at low dNTP concentrations, compared to
FeLV RT (and MuLV RT). A previous study that used
multiple nucleotide incorporation assays (North et al., 1994)
reported higher Km values of FIV RT than those observed in
this study. The kinetic values of DNA polymerases also
widely vary depending on the type of assay (i.e., single or
multiple nucleotide incorporation) and nature of substrates
used (i.e., templates and template sequences). In addition, the
FIV strain used in this earlier study is different from the strain
(FIV-PPR) used in this study. Therefore, to verify differences
in the DNA synthesis rate difference between FeLVand FIV
RTs at low dNTP concentrations, we examined the multi-
round primer extension capabilities of FeLV and FIV RTs at
various dNTP concentrations using a 38-mer heteropoly-
meric RNA template, using HIV-1, SIVMNE CL8, MuLV,
and AMV RTs for comparison. Indeed, we found that the
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than the oncoretroviral RTs at low dNTP concentrations (i.e.,
0.05 AM, Fig. 3), consistent with their Km differences
observed in Fig. 2. The lowest dNTP concentrations used
in this experiment, 0.2 and 0.05 AM, are much lower than the
Km values of the oncoretroviral RTs, but near theKm values of
the lentiviral RTs. Further experiments employing pre-steady
state assays will be necessary to further elucidate mechanistic
elements that kinetically differentiate FIV and FeLV RTs.
Contributions of the dNTP utilization efficiency differ-
ence between RTs of these two retrovirus groups on viral
characteristics have not been clearly discussed. One viro-
logical difference between lentiviruses and oncoretroviruses
is their cell type specificity. Oncoretroviruses productively
replicate primarily in actively dividing cells (e.g., activated T
cells), while lentiviruses efficiently infect both dividing cells
and non-dividing/terminally-differentiated cells (e.g., macro-
phage) (Gendelman et al., 1986; McGuire and Henson,
1971). For example, MuLV infection requires cell prolifer-
ation (Lewis and Emerman, 1994; Lewis et al., 1992) and
AMV infects dividing macrophages (Durban and Boettiger,
1981a, 1981b). Recent studies employing Avian Sarcoma
Virus (alpharetrovirus) have shown that ASV is capable of
mounting an infection of non-dividing cells (Greger et al.,
2004; Hatziioannou and Goff, 2001; Katz et al., 2002).
However, these studies employ either a modified version of
the virus, or use vector systems based on ASV, and not the
naturally occurring virus. Moreover, most of the studies
conducted use murine neurons, HeLa, or human fibrosar-
coma cell lines, none of which are the natural hosts of ASV. In
addition, productive replication of this virus requires dividing
chicken embryo fibroblast cells (Estis and Temin, 1979).
Numerous studies have demonstrated that non-dividing
cells have lower dNTP concentrations than dividing cells
(Traut, 1994). Recently, we determined that the dNTP
concentration of human macrophage to be approximately
40 nM, which is roughly 50–100 times lower than that of
activated T cells (2–5 AM) (Diamond et al., 2004).
Interestingly, the Km values for dNTPs of lentiviral and
oncoretroviral RTs studied here are near the dNTP concen-
tration in macrophage and activated T cells, respectively.
Therefore, kinetic comparisons of RTs from these two
retroviral groups (Fig. 2) support the idea that RTs of
retroviruses may have evolved to efficiently execute DNA
synthesis in the specific host cells that support productive
infection. It is likely that the dNTP concentration level in
feline macrophage, a known target for several strains of FIV
(Dean et al., 1999), is well below the dNTP concentration that
can be found in activated feline Tcells although this has yet to
be confirmed. The ability of FIV RT to synthesize DNA at
low dNTP concentrations would certainly be a factor in the
ability of FIV to replicate in macrophage. In contrast, the
higher Km values of the RT of the FeLV 61E strain and the T
cell tropism of this virus imply that the active site of the 61E
FeLV RT may have adapted to the high dNTP concentration
environment of T cells. This possibility can be furthersupported by our recent observation that HIV-1 variants
harboring HIV-1 RT mutants which kinetically mimic
oncoretroviral RTs in having reduced DNA polymerization
capability in low dNTP concentration environments, failed to
infect macrophage even though these mutant HIV-1s
successfully infected dividing cells such as activated CD4+
T cells and transformed cell lines containing high dNTP
concentrations (Diamond et al., 2004).
In three different assays presented in this work, FeLV RT
showed higher fidelity than FIV RT. The M13mp2 lacZa
forward mutation assay showed that FeLV RT has an 11-fold
higher fidelity than FIVRT. In previous studies, RTs ofMuLV
RT and AMV RT showed 12- to 15-fold higher fidelity than
HIV-1 RT (Roberts et al., 1989). We previously reported that
SIVCL8 RTalso has low fidelity (Diamond et al., 2001). This
combined evidence supports previous data indicating that
lentiviral RTs have a lower fidelity than non-lentiviral RTs
studied thus far. It is becoming increasingly apparent that the
fidelity of RTs plays important roles in viral genomic
mutagenesis. Recent studies using pseudotyped viruses
demonstrated that RT, but not host RNA polymerase II, is
responsible for viral genetic mutagenesis (O’Neil et al.,
2002). It was also recently reported that pseudotyped HIV-1
containing various RT mutants with high fidelity drove down
viral mutation rates during a single round of infection
(Mansky et al., 2003; Weiss et al., 2004). Furthermore,
similar pseudotyped systems containingHTLV showed lower
mutation rates than HIV-1 (Mansky, 2000). We predict that
differences in the fidelity of the FeLVand FIV RTs observed
in this study very likely reflects different mutation rates
between these two retroviruses. Further kinetic studies such
as pre-steady state kinetic analysis will elucidate mechanisms
of the fidelity difference between these enzymes.
In looking at the divalent cation usage of our recombi-
nant proteins, we see that the FIV and FeLV RTs show
similar patterns of metal dependence compared to HIV-1
and MuLV RTs, respectively. The similar requirement of
FIV RT for Mg2+ to HIV-1 RT is consistent with a report by
North et al. (1994), while the preference for Mn2+ by FeLV
is consistent with a previous report by Rho and Gallo
(1980). The results presented here are also consistent with
older reports studying metal usage by RTs (Gerard and
Grandgenett, 1975; Valverde-Garduno et al., 1998).
It was previously found that 3TCTP is not an efficient
inhibitor for MuLV RT (Cherrington et al., 1996), whereas
wild type HIV-1 RT is efficiently inhibited by 3TCTP
(Boyer et al., 2002). This 3TCTP sensitivity difference can
be attributed to the sequence difference at the X residue in
the conserved YXDD region (Rezende et al., 1998). RTs of
MuLV and HIV-1 have Val and Met residues at their YXDD
sequence, respectively (See Fig. 1A). This possibility was
further supported by the clinical finding that 3TC-resistant
HIV-1 variants contain the M184V (or M184I) RT mutation
in the YMDD motif (Back et al., 1996). Structural analysis
demonstrates that the Val mutation to the YMDD sequence
of HIV-1 RT prevents entry of dNTP analogs containing a
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site (Gao et al., 1993; Sarafianos et al., 1999). Our results
clearly demonstrate that FeLV RT is less sensitive to 3TCTP
than FIV RT. The presence of Val and Met at their YXDD
catalytic sites of FeLV and FIV RTs (Fig. 1A), respectively,
very likely contributes to the difference in inhibitory effects
of 3TCTP on the DNA polymerase activity of these two RT
proteins. A known FIV RT Met-to-Thr mutation at the
analogous position in the YXDD motif confers 3TC
resistance (Smith et al., 1997). However, viral sensitivity
of FeLV and FIV to 3TC has not been directly compared. In
contrast to 3TCTP, we observed that both FIV and FeLV
RTs are sensitive to AZTTP even though FeLV RT is
slightly less sensitive than FIV RT (Fig. 7B). It was
previously demonstrated that MuLV RT is less sensitive to
AZTTP than HIV-1 RT (Quan et al., 1998). AZT and 3TC
are drugs used in anti-FIV therapy. AZT in particular has
been studied both in monotherapy and in combination with
other drugs for the treatment of FIV infection both in vivo
and in vitro (Arai et al., 2002; Bisset et al., 2002; North et
al., 1989). In vitro studies have shown that AZT/3TC
treatment, in combination with abacavir, is effective in
preventing FIV replication, similar to what has been seen in
HIV therapy (Bisset et al., 2002). A recent study has shown
that AZT/3TC combination therapy is a good prophylactic
for preventing infection, and that the treatment can either
prevent or delay seroconversion when administered near the
time of infection. The same report shows that the therapy
can prevent replication of FIV in primary PBMC (Arai et
al., 2002). In contrast, the treatment of the FeLV infection
with 3TC has not been reported. However, AZT has been
used for treating FeLV infection. Inhibition of FeLV
replication by AZT was observed in in vitro studies (Mathes
et al., 1992). For in vivo treatments, proper dosage of AZT
can prevent antigenemia, but not seroconversion, indicating
that the treatment is not effective for preventing primary
infection. This seems to be true for both prophylactic
treatment as well as AZT treatment post-infection (Mathes
et al., 1992).
In addition, replication inhibition of both FIV and FeLV
by ddI was observed in in vitro studies (Meldin et al., 1996;
Mukherji et al., 1994). The IC50 values of FIV (FIV-PPR)
and FeLV (61E), which are determined using the same
conditions, are not currently available. This in vitro culture
data can be used to address the enzymatic inhibition profile
differences observed in this study. In fact, the biochemical
IC50 values determined for any inhibitor may be different
when employing different assays (i.e., single nucleotide
addition vs. multi-nucleotide addition), different templates,
and may also be dependent on the neighboring sequence
variation (i.e., secondary structure) of the template. Our data
also show that ddATP is an effective inhibitor of FIV RT.
This is consistent with a previous report that showed that
ddATP was an effective inhibitor of FIV RT activity when
using AX-174 ssDNA as a template (Cronn et al., 1992).
The same report demonstrates that, in vitro, ddA is aneffective inhibitor of FIV viral replication to both wild-type
and AZT-resistant strains of FIV.
The data presented in this study with purified FIV and
FeLV RT proteins contribute to validating the enzymatic
differences found thus far between lentiviral and oncoretro-
viral RTs currently studied in the literature. These enzymatic
differences observed between these two groups of retro-
viruses appear to be related with their virological differences.
More specifically, enzymatic differences between lentiviral
and non-lentiviral RTs in the Km values, fidelity and drug
sensitivity may correlate to virological differences in cell type
specificity, genomic mutation rate and sensitivity to nucleo-
side RT inhibitors. Therefore, this observation suggests that
RTs of retroviruses may have evolved to facilitate viral
replication within the specific cellular environments that
these two groups of retroviruses encounter upon infection.
Indeed, characterization of more RT proteins from various
retroviruses and relating the biochemical findings to viro-
logical properties of each retrovirus (i.e., cell type specificity
and drug sensitivity) will shed light on unique evolutionary
and virological roles of RT.Materials and methods
Strains and plasmids
Escherichia coli NM522 (Stratagene, CA) was used
during the construction of plasmids; E. coli BL21 (DE3)
pLysS (Novagen, WI) was used for over-expression of RT
proteins. Hexahistidine-tagged p66/p66 HIV-1 RT (Weiss et
al., 2002), p66/p66 SIVMNE CL8 RT (SIV RT (Diamond et
al., 2001)), and MuLV RT proteins (Malboeuf et al., 2001)
were purified as described previously. AMV RT was
purchased from Stratagene (CA). pFIV-PPR (Phillips et
al., 1990; Talbott et al., 1989), which encodes the full-length
genome of FIV-PPR, was obtained from Dr. John Elder
through the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH. p61E (Donahue
et al., 1988; Overbaugh et al., 1988), which encodes the full-
length genome of FeLV-61E, was similarly obtained from
Dr. James Mullins. pET28a (Novagen) was used for over-
expression of FIV and FeLV RT proteins in BL21 (DE3)
pLysS. DNA oligomers used in this study were obtained
from Integrated DNA Technologies (IA).
Construction of FIV and FeLV RT expression plasmids
The N-terminal (N-T) and C-terminal (C-T) sequences of
FIV and FeLV RT proteins were determined by aligning
positions of the conserved YXDD sequences of HIV-1 and
MuLV RTs (i.e., Asp185 of HIV-1 RT and Asp224 of MuLV
RT), respectively, using Jellyfish 1.5 (LabVelocity, CA) to
determine both alignment and sequence similarity. The RT
proteins were not cloned according to the precise cleavage
site within the pol polyprotein because this information has
D.J. Operario et al. / Virology 335 (2005) 106–121 117thus far not been published. The FIV RT gene encoding 560
amino acid residues was amplified from pFIV-PPR using N-
T primer (5V-AAAAAAAAACATATGCAAATTTCTGA-
TAAGATTCC-3V) and C-T primer (5V-AAAAAAGAGCTC-
GAGTTACCCTTCTATTATCATCATTG-3V). The FeLV RT
gene, encoding 668 amino acid residues, was amplified
from p61E using N-T primer (5V-AAAAAAAAACATAT-
GACTCTACAATTAGAAGAG-3V) and C-T primer (5V-
AAAAAAAAAAAGCTTTTATAAGATGGTTAGTGAT-
GATTG-3V). The amplified RT genes were inserted into
pET28a using NdeI and XhoI (FIV RT) or NdeI and HindIII
(FeLV RT), generating pFIVRT and pFeLVRT, respectively.
The cloned RT genes in pET28a are fused to sequences
coding for a hexahistidine tag and a Thrombin cleavage site
at their N-T ends. The N-T 1.2 kb regions of these cloned
RT genes were sequenced to confirm each RT clone.
Purification of RT proteins
The hexahistidine-tagged FIV and FeLV RT proteins
were purified using protocols, reagents, and buffers pro-
vided by the manufacturer (Novagen). The expression of
FIV and FeLV RT proteins was induced at an OD600 = 0.1
with 1 mM IPTG for 3 h at 37 -C in BL21 (DE3) pLysS
harboring pFIVRT or pFeLVRT. The harvested cell pellets
were resuspended in 1 Binding Buffer, and kept at 70 -C
overnight. The frozen cell pellets were thawed on ice for 2
h, then centrifuged for 15 min (12,000  g at 4 -C). RT
proteins were purified from the cell lysates using Ni2+
chelation chromatography (Novagen) as previously
described (Kim, 1997). Purified proteins were dialyzed
against 500 mL 1 Dialysis Buffer (50 mM Tris–HCl pH
7.5, 1 mM EDTA, 200 mM NaCl, 10% glycerol) at 4 -C for
12 h. The dialyzed proteins were treated with biotinylated
Thrombin under the conditions recommended from the
manufacturer (Novagen). After removing the biotinylated
Thrombin from the digested RT solutions by Stravidine
columns (Novagen), the RT proteins were re-applied to Ni2+
chelation chromatography, and the flow-through fractions
containing digested RT proteins were pooled for dialysis
against 1 Dialysis Buffer with DTT (1 mM) for an
additional 12 h at 4 -C. Amounts of purified proteins were
estimated in the Bradford assay (BioRad, CA) with a bovine
serum albumin standard; most preparations had >90%
purity, estimated by visual inspection of Coomassie Blue-
stained SDS-polyacrylamide gels. With this protocol, we
were able to purify 0.2–0.5 mg of RT proteins from each 1
L culture. Purified proteins were also assayed for RNase
contamination. Reaction mixtures contained purified RT
(FIV RT: 64 nM, FeLV RT: 96 nM), 10 nM template/primer
(see Primer extension assay below), 25 mM Tris–HCl (pH
8.0), 100 mM KCl, 2 mM DTT, 5 mM MgCl2, 10 AM
(dT)20, 0.1 mg/ml bovine serum albumin, and no dNTP.
Reactions were carried out at 37 -C for 5 min, and then
terminated with the addition of 4 Al of 40 mM EDTA, 99%
formamide. Reaction products were then denatured byincubation at 95 -C for 3 min. Denatured products were
analyzed by electrophoresis on 14% polyacrylamide-urea
denaturing gel.
FIV RT p66/p66 dimer was used in this study, and a
previous study of FIV RT shows that the p66/p66
homodimer does shows comparable activity to the p51/p66
heterodimer (Amacker et al., 1995).
Primer extension assay with DNA or RNA templates and
Misincorporation assay
Procedures were modified from those of Preston et al.
(1988). The template-primer was prepared by annealing a
38mer RNA template (5V-GCUUGGCUGCAGAA-
UAUUGCUAGCGGGAAUUCGGCGCG-3V, Dharmacon
Research, CO) or 38mer DNA template (5V-GCTTGG
CTGCAGAATATTGCTAGCGGGAATTCGGCGC G-3V)
to a 17-mer DNA (5V-CGCGCCGAATTCCCGCT-3V, A-
primer or 5V-GCCGAATTCCCGCTAGCAATATT-3V
Extend-C primer) 32P-labeled at the 5V end using
[g-32P]ATP and T4 polynucleotide kinase (template/primer,
2.5:1). Reaction mixtures (20 Al) contained 10 nM
template/primer, RT proteins showing the same DNA
polymerase activities indicated below, 3 or 4 dNTPs
(250 AM each dNTP) in multiple extension assays or only
dCTP in single nucleotide extensions (see Fig. 2B legend
for concentrations), 25 mM Tris–HCl (pH 8.0), 100 mM
KCl, 2 mM DTT, 5 mM MgCl2, 10 AM (dT)20, 0.1 mg/ml
bovine serum albumin. Approximately 50% of the primer
was fully extended by 40 nM FIV RT and 60 nM FeLV
RT under this reaction condition. Reactions were incubated
at 37 -C for 5 min and terminated by 4 Al of 40 mM
EDTA, 99% formamide. Under this reaction condition the
level of the fully extended primer was linear to RT
concentrations used (i.e., as used in Fig. 3; concentrations
designated 1 and 4 in Figs. 4 and 5: HIV-1 RT 16 nM
and 4 nM, FIV RT: 64 nM and 16 nM, MuLV RT: 8 nM
and 2 nM, FeLV RT: 96 nM and 24 nM.). Reaction
products were immediately denatured by incubating at 95
-C for 3 min and analyzed by electrophoresis on 14%
polyacrylamide-urea denaturing gels.
Extension of mismatched primers
To measure the capability of each RT to extend
mismatched primer, we used two different mismatched
primers, G/T and C/A. G/T mismatched primer (5V-
CGCGCCGAATTCCCGT-3V) was annealed to the 38-mer
RNA template (see above) with the G/T mismatch at the 3V
end nucleotide underlined. C/A mismatched primer (5V-
CGCGCCGAATTCCCGCTAA-3V) was annealed to the 38-
mer DNA template (see above) with the C/A mismatch at
the 3V end nucleotide underlined. Extension conditions for
these mismatched primers were the same as in the
misincorporation assay described above except 10 min
incubation and T/Ps. Equal RT activities of RT proteins
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primer (see above) were used for the extension of the two G/
T and C/A mismatched primers. The reactions were
incubated at 37 -C for 10 min. The reactions were also
analyzed by 14% denaturing gel.
Steady state kinetic analysis of RT proteins
The steady state kinetic assay protocol described by
Boosalis et al. (1987) was modified to determine DNA
polymerization efficiencies (kcat/Km) of RT proteins. Reac-
tion conditions were the same as those described in the
misincorporation assay except for primers and dNTP
concentration. For the analysis of four individual dNTP
incorporation kinetics, four different primers (A-, G-, C-,
and T-primers for dATP, dGTP, dCTP and dTTP incorpo-
ration) annealed to the 38-mer RNA template (see above)
were used. The sequence of the A-primer was described
above in misincorporation assay, and the sequences of the
G-(18-mer), C-(19-mer) and T-(16-mer) primers are the
same as A-primer except their 3V ends either extended or
shortened from the A-primer based on the template
sequence (see Primer extension assay above). The amounts
of RTs and incubation time were adjusted to yield extension
of 30–40% of the total labeled primer (200 fmol) at the
highest dNTP concentration (500 AM), which is at least 5
times higher than the Km values. Then, the reactions were
repeated with decreasing 8 concentrations of each dNTP.
Products were resolved in 14% polyacrylamide-urea gel and
quantitated by phosphor-imaging analysis (Cyclone, Perki-
nElmer, CA). The percent of primer extension for each
reaction was used to calculate the kcat and Km values by the
Lineweaver–Burke plot as described by Creighton and
Goodman (1995).
M13mp2 lacZa forward mutation assay
The fidelity for the purified RT proteins was measured
essentially as previously described (Bebenek and Kunkel,
1995; Weiss et al., 2000). M13mp2 DNA containing a
361-nucleotide single-stranded gap was prepared as
specified (Weiss et al., 2000). Gapped M13mp2 DNA (1
Ag) was incubated with RTs (0.5 Ag) at 37 -C for 20 min
under the conditions described above for the misincorpo-
ration assays. The gapped DNAs incubated with RTs were
analyzed by 0.7% agarose for examining the production of
double strand M13 DNA with filled gaps (Weiss et al.,
2000). Three independent gap-filling reactions per RT
protein were performed. The extended gapped DNAs were
transformed to MC1016 cells, and the transformed cells
were plated to M9 plates containing X-gal (50 Ag/ml) and
IPTG (1 mM) with CSH50 lawn cells. Phenotype of
4000–6000 plaques per gap-filling reaction was examined.
The mutant frequency was determined as the ratio
between number of mutant plaques (pale blue and/or
clear) and number of mutant plus wild type (dark blue)plaques. Five mutant phages in each RT assay were
isolated and the gap regions in the mutant phage DNAs
were sequenced. All mutants analyzed had a mutation in
the gapped region.
Comparison of RT activities in the presence of either Mg2+
or Mn2+
A test of preference for divalent cation was performed
using a template-primer complex of homopolymeric
poly(rA) (286–428 nt, Amersham Pharmacia, NJ)
annealed to a 20-nt oligo(dT) primer (Amersham-Pharma-
cia) (template/primer ratio 1:4) as a substrate. Reaction
mixtures (20 AL) contained approximately 0.1 Ag purified
RT proteins, 25 mM Tris–HCl (pH 8.0), 100 mM KCl, 2
mM DTT, 3H-TTP (10 AM, Amersham-Pharmacia), dTTP
(100 AM), and either MgCl2 or MnCl2 at either 0.05 mM
or 5 mM final concentration. Reactions were carried out in
duplicate at 37 -C for 5 min. FIV RT, FeLV RT, HIV-1 RT,
and MuLV RT were all examined in this manner. The assay
protocol has been previously described (Kim et al., 1996).
Sensitivity of RT proteins to 3TCTP, AZTTP, and ddATP
The assay for sensitivity of RT proteins to these NRTIs
was the primer extension assay described above with the
T/P (17-mer A-primer and 38-mer RNA template; see
above) and mixtures of natural dNTPs (10 AM) and
varying concentrations of 3TCTP (Moravek, CA), AZTTP
(Moravek), or ddATP (Amersham-Pharmacia). Polymerase
activity of RT proteins, which showed ¨80% primer
extension in the absence of NRTIs under the reaction
condition described in misincorporation assay, was chosen.
Extension products were analyzed on 14% polyacrylamide-
urea denaturing gel. The percent of full extension (38 nt)
was determined by comparing products extended in the
presence of different concentrations of NRTI with product
produced in the presence of dNTPs only (i.e., no drug).Acknowledgments
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